Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "2022"

1466 News Found

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
Drug Approval | October 26, 2023

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer


Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer
News | October 25, 2023

Sumitomo Pharma announces authorization in Canada of Orgovyx for treatment prostate cancer

Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada


RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr
News | October 23, 2023

RPG Life Sciences posts Q2 FY24 PAT at Rs. 25.86 Cr

RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023


Indoco Remedies posts consolidated Q2FY24 PAT at Rs. 35.08 Cr
News | October 23, 2023

Indoco Remedies posts consolidated Q2FY24 PAT at Rs. 35.08 Cr

The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023


Aarti Drugs Q2 FY24 consolidated net profit drops QOQ to Rs. 39.59 Cr
News | October 21, 2023

Aarti Drugs Q2 FY24 consolidated net profit drops QOQ to Rs. 39.59 Cr

Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023


Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr
News | October 21, 2023

Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr

Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023


Need to include ASMD as a notified condition in the National Policy for rare diseases
Policy | October 20, 2023

Need to include ASMD as a notified condition in the National Policy for rare diseases

ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another


Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes
News | October 18, 2023

Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually


Venus Remedies expands reach with the launch of Elores in Ecuador
News | October 14, 2023

Venus Remedies expands reach with the launch of Elores in Ecuador

The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries


Lupin gets tentative approval from USFDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution
Drug Approval | October 13, 2023

Lupin gets tentative approval from USFDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch